Altor BioScience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

Altor BioScience Corporation announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). The FDA’s Fast Track program is designed to expedite the development and review of drugs to treat serious conditions and fill unmet medical needs.

 

Read More

NantHealth, NantKwest and NantOmics Announce Availability of GPS Cancer and Phase I-III QUILT Trials Through the U.S. National Institute of Health's ClinicalTrials.gov

NantHealth, Inc., a leading next-generation, evidence-based, personalized healthcare company, together with NantKwest and NantOmics, today announced the public availability of QUILT Programs (Quantum Immuno-oncology Lifelong Trial), aimed to harness and orchestrate all elements of the immune system through the testing of novel treatment combinations, within the national clinical trials database, www.ClinicalTrials.gov

Read More

NantCare Unveils Solutions to Support CMS Oncology Care Model

NantCare Unveils Solutions to Support CMS Oncology Care Model

NantCare, a member of the NantWorks will be providing community oncology practices with solutions and resources that will help these practices comply with the administrative and clinical requirements put forth by the CMS’ new Oncology Care Model (OCM). Typically only available at large cancer institutions,  NantCare will provide access to clinical trials through facilitation of participation in Cancer Breakthrough 2020’s QUILT Trials, eliminating the need for patients to travel to major cancer centers for care and treatment.

 

Read More at HIT Consultant

Read More

Cancer Breakthroughs 2020 will arm oncologists with new tools

Cancer Breakthroughs 2020 will arm oncologists with new tools

In 2016, more than 1.6 million new cases of cancer will be diagnosed and cancer will kill an estimated 600,000 Americans. "When a patient is first diagnosed with cancer, they are overwhelmed with a sense of uncertainty. Our goal is to develop personalized immunotherapeutic treatment options and arm oncologists with the necessary tools to combat cancer with certainty," says Dr. Patrick Soon-Shiong in an interview with Managed Healthcare Executive. 

Read More